Clinical Trial

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients. The main objectives of this study are: * To determine the therapeutic efficacy of HbF inducers (combination therapy: thalidomide and hydroxyurea) on hemoglobin level and blood transfusion in beta thalassemia patients. * To determine the safety of HbF inducers (combination therapy: thalidomide and hydroxyurea) in beta thalassemia patients * To determine effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on quality of life of beta thalassemia patients
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-07
Trial Details
NCT Number NCT07673302
Lead Sponsor Riphah International University
Conditions Thalassemia
Enrollment 240 participants
Start Date 2026-06-20
Primary Completion 2027-06-19 (estimated)
Study Completion 2027-06-19 (estimated)
Updated on ClinicalTrials.gov 2026-08-06